首页/数据集/RNAseq of A375 melanoma cells and A375 with ARID1A KO in control conditions and treatment with trametinib, vemurafenib or combination

RNAseq of A375 melanoma cells and A375 with ARID1A KO in control conditions and treatment with trametinib, vemurafenib or combination

ChEBI2025-02-18 更新2026-07-12 收录

黑色素瘤药物研发

癌症RNA测序

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-MTAB-14759 数据链接链接失效反馈

官方服务：

资源简介：

RNAseq of A375 melanoma cells and A375 with ARID1A KO in control conditions and treatment with trametinib, vemurafenib or combination

应用场景：

创建时间：

2025-02-18

癌症RNA测序

基因表达分析

This dataset represents RNA-sequencing data from 278 primary colon cancers obtained from fresh-frozen tumor sections. RNA-sequencing was performed using TruSeq library preparation and samples were seq

NIAID Data Ecosystem140

135f4f3b-a456-48a0-a679-489ed4fdcbf8 - samples

癌症RNA测序

Barrett食管研究

A comprehensive RNA repository (both coding and non-coding) from 17 patients diagnosed with esophageal adenocarcinoma, high-grade dysplastic or non-dysplastic BarrettÃ¢Â€Â™s esophagus. Per patient, a

NIAID Data Ecosystem60

Genome-wide expression profile of human melanoma cell line WM3248 treated with ARN22089 at 0, 4, 6 ÂµM dosing for 24 h

黑色素瘤药物研发

药物转录组学

To determine pathways engaged by ARN22089 in melanoma cells in-vitro; identify transcripts that are up- or down-regulated in the presence of ARN22089. Overall design: Human melanoma cell line (WM3248)

NIAID Data Ecosystem50

The PPAR agonist Rosiglitazone induces paracrine signaling in melanoma cells that activate stromal cells and enhances tumor growth.. The PPAR agonist Rosiglitazone induces paracrine signaling in melanoma cells that activate stromal cells and enhances tumor growth.

黑色素瘤药物研发

肿瘤微环境

Besides improving insulin sensitivity in type 2 diabetes, the thiazolidinedione family of compounds and the pharmacologic activation of their best characterized target PPARg has been proposed as a the

NIAID Data Ecosystem70

A novel Chalcone derivative has antitumor activity in melanoma by inducing DNA damage through the upregulation of ROS products

黑色素瘤药物研发

ROS诱导DNA损伤

Melanoma is one of the most aggressive tumors with the remarkable characteristic of resistance to traditional chemotherapy and radiotherapy. Although targeted therapy and immunotherapy benefit advance

NIAID Data Ecosystem50

RNAseq of A375 melanoma cells and A375 with ARID1A KO in control conditions and treatment with trametinib, vemurafenib or combination

资源简介：

相关数据集